Use of Real-World EMR Data to Rapidly Evaluate Treatment Effects of Existing Drugs for Emerging Infectious Diseases: Remdesivir for COVID-19 Treatment as an Example-Reference-Cited by-同舟云学术

Use of Real-World EMR Data to Rapidly Evaluate Treatment Effects of Existing Drugs for Emerging Infectious Diseases: Remdesivir for COVID-19 Treatment as an Example

Published:2024-01-02 Issue: Volume: Page:
ISSN:1867-1764
Container-title:Statistics in Biosciences
language:en
Short-container-title:Stat Biosci

Author:

Zhang Chenguang,Nigo Masayuki,Patel Shivani,Yu Duo,Septimus Edward,Wu Hulin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Statistics and Probability

Link

https://link.springer.com/content/pdf/10.1007/s12561-023-09411-8.pdf

Reference64 articles.

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus, I., & Research, T (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017

2. Geneva: World Health Organization (2023) WHO COVID-19 Dashboard. https://covid19.who.int/

3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR et al (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383(19):1813–1826. https://doi.org/10.1056/NEJMoa2007764

4. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn M-Y, Nahass RG, Chen Y-S, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM et al (2020) Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med 383(19):1827–1837. https://doi.org/10.1056/NEJMoa2015301

5. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang S-C, SenGupta D, Hyland RH, Osinusi AO et al (2020) Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324(11):1048–1057. https://doi.org/10.1001/jama.2020.16349